Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octreotide implant
- Development stage
- Discontinued
- Lead developer
- Endo International
- Modality
- Peptides, Hydrogel Systems → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
The octreotide implant is a 6-month, subcutaneous hydrogel-based delivery system developed by Endo Pharmaceuticals for the treatment of acromegaly. Utilizing HYDRON polymer technology, the implant provides sustained release of octreotide, a synthetic cyclic peptide and somatostatin analog. Octreotide acts as an agonist at somatostatin receptors, particularly SSTR2 and SSTR5, which leads to the inhibition of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion. The implant was designed to provide a more convenient alternative to monthly long-acting release (LAR) injections. While the product reached Phase III clinical trials, development was discontinued around 2011.
- Other names
- octreotide hydrogel implantEndo octreotide implantoctreotide subcutaneous implant
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR5 (Somatostatin receptor 5)
Beyond the preview
Go deeper on octreotide implant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octreotide implant.